Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Creatine Monohydrate

Plain-language summaryIntrigue 75 / 100

Creatine is a small organic acid your body builds from arginine, glycine, and methionine, and stores almost entirely in skeletal muscle as phosphocreatine. The phosphocreatine pool serves as a rapid phosphate donor that regenerates ATP during high-intensity exercise. Supplementation expands that pool by roughly 20 to 40 percent, which translates to consistent gains of 5 to 10 percent in strength and power output across hundreds of trials. It is the most thoroughly studied ergogenic supplement, with stronger evidence than essentially anything else in the sports nutrition aisle. Newer research has expanded into cognition, neurodegenerative disease, and depression on the theory that creatine kinase activity matters in the brain too. Loading at 20 g per day for five days saturates muscle as fast as 3 to 5 g per day over three to four weeks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

38/100

The gold standard ergogenic reference compound, too settled to be a compelling research target

Cap applied Foundational metabolite (max 38)

Look, creatine monohydrate is genuinely excellent at what it does. The phosphocreatine-to-ATP pathway is one of the cleanest mechanisms in exercise physiology, and the evidence base is staggering: hundreds of replicated trials across decades, consistent 5 to 10 percent improvements in strength and power output, meaningful lean mass effects. If you’re doing sport science or exercise physiology, this is the reference standard. You build your protocols around it.

The problem is that none of that makes it an interesting research target right now. The mechanism was settled in the 1990s. The loading vs maintenance debate (20 g/day for 5 days versus 3-5 g/day sustained, same endpoint, different timeline) was resolved years ago. The sourcing landscape is essentially a commodity market, which is great for reliability and terrible for differentiation. When something this well-understood is this cheap and this consistent, it stops being a research frontier and becomes infrastructure.

The emerging cognitive angle is worth noting, and we dont want to dismiss it entirely. Creatine kinase activity in the CNS is real biology, and there are small trials suggesting some signal in traumatic brain injury populations and mild depression. Watanabe and colleagues published on cognitive effects in vegetarians, where baseline brain creatine is predictably lower, and the effect size there is actually interesting. But honest appraisal puts this at the “plausible mechanism, replication needed” stage. It’s not a reason to score the compound higher when the primary ergogenic story has been exhausted for three decades.

What keeps creatines bench value positive is its role as the canonical ergogenic comparator. If you’re testing anything in the energy substrate or high-intensity power output space, you’re measuring against creatine. It’s the reference standard the field uses to anchor effect sizes. That has real utility, but it’s the utility of a ruler, not a discovery.

The score here is intentional. Creatine monohydrate is one of the most effective and well-documented supplements in existence, and we mean that without irony. It scores 38 precisely because this rubric asks about research frontier value, not product quality. A compound that has been fully characterized, whose mechanism generates no new hypotheses, and whose clinical application is essentially saturated is not where a serious bench scientist should be directing attention in 2026. We’d recommend it without hesitation in a protocol stack. We wouldn’t fund a primary research program around it.

Novelty

12

Mechanism promise

18

In-category differentiation

45

Evidence quality

80

Translational signal

72

Research bench value

40

Rationale Creatine monohydrate scores well on evidence quality and translational signal but near-zero on novelty and mechanism, producing a raw calculated score of 42; the foundational metabolite hard cap brings this to 38. The compound is exhaustively characterized and functions as research infrastructure rather than a research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous metabolite / ergogenic supplement

A nitrogenous organic acid; the most thoroughly studied ergogenic supplement; phosphocreatine pool expansion supports rapid ATP regeneration during high-intensity exercise.

Abstract

Creatine monohydrate (N-(aminoiminomethyl)-N-methylglycine; CAS 6020-87-7; molecular formula C4H9N3O2 (anhydrous); molecular weight 131.13) is a nitrogenous organic acid biosynthesized in the liver and kidneys from arginine, glycine, and methionine and stored in skeletal muscle (95 percent of body creatine pool). Mechanism: phosphocreatine, the phosphorylated storage form, donates phosphate to ADP via creatine kinase to rapidly regenerate ATP during high-intensity exercise; supplementation expands the muscle phosphocreatine pool by approximately 20 to 40 percent, supporting longer high-intensity efforts. The most thoroughly studied ergogenic supplement, with hundreds of trials demonstrating consistent ~5 to 10 percent improvement in strength and power output and meaningful effects on lean body mass. Emerging interest in cognitive enhancement, neurodegenerative disease (creatine kinase activity in brain), and depression. The 5-day loading protocol (20 g/day) versus daily maintenance (3 to 5 g/day) produces equivalent muscle saturation with maintenance over 3 to 4 weeks. Plasma half-life is approximately 3 hours; muscle storage is the relevant pharmacokinetic measure. Used as the canonical ergogenic supplement in sport science and exercise physiology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-394Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
SRT1720

Plain-language summaryIntrigue 50 / 100

SRT1720 is the structural ancestor of SRT2104, the original imidazothiazole SIRT1 activator from Sirtris (now GSK), about 1000 times more potent than resveratrol at SIRT1. Mouse studies showed lifespan extension in diet-induced obese mice and improvement in age-related metabolic and pathological markers. SRT2104 was later derived from this scaffold with better human pharmacokinetic properties. Whether SIRT1 activation is the actual mechanism for the in vivo effects has been disputed for over a decade, with some labs unable to reproduce the activation chemistry in cell-free assays. Important historically as the proof-of-concept compound for the sirtuin pharmacology program, but limited human relevance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

40/100

Superseded sirtuin probe with real mouse pharmacology but no translational runway

Look, SRT1720 occupies a specific and somewhat awkward position in the sirtuin literature. It was the headline compound out of Sirtris Pharmaceuticals before GlaxoSmithKline acquired the outfit in 2008, and for a few years it was the sharpest tool available for interrogating SIRT1 biology in rodents. The roughly 1000-fold potency advantage over resveratrol as a SIRT1 activator was real, the mouse lifespan extension data in diet-induced obese animals published by Milne and colleagues held up on replication, and the metabolic phenotype work was genuinely interesting. We think that body of rodent data is still the compound’s main selling point in 2025.

Here’s the thing, though. The mechanism controversy matters. In 2010, Pacholec et al. published in the Journal of Biological Chemistry arguing that SRT1720 and related compounds were activating SIRT1 only in the context of fluorescent substrate assays, not with natural peptide substrates, implying the whole activation story was a biochemical artifact. That paper hit the field hard. The 2013 Hubbard et al. work in Science partially rehabilitated the allosteric mechanism by showing activation does occur with certain natural substrates containing hydrophobic motifs adjacent to the acetyl-lysine, but the qualification is load-bearing: not all SIRT1 substrates respond equally, and the interpretation of older studies using this compound gets complicated fast. Serious investigators working in this area now have to navigate that literature carefully.

The differentiation story is equally constrained. SRT2104 was explicitly developed as the human-ready successor, with improved metabolic stability and PK that actually support clinical dosing. SRT2104 has been in human trials (inflammation, muscle atrophy, Type 2 diabetes endpoints). SRT1720 has not. That division of labor is by design, and it means SRT1720 is basically a rodent-only probe at this point. If your research program lives in mouse models and you’re specifically asking questions about SIRT1-dependent metabolic or longevity phenotypes, the established pharmacology is genuinely useful and the plasma half-life around 8 to 10 hours in rodents is well characterized. Outside of that narrow use case, you’re better served by SRT2104 for anything translational.

What we dont see here is a strong argument for prioritizing SRT1720 over other tools in sirtuin biology. EX-527 handles the inhibitor side cleanly. SRT2104 handles the human-relevant activation angle. SRT1720 sits in the middle as a historically important compound that still earns its place on the shelf for specific rodent studies, but that’s a qualified endorsement. The mechanism overhead, the translational ceiling, and the fact that theres a better successor compound all push this toward the lower tier of the library despite the real and replicated mouse data underpinning it.

Novelty

35

Mechanism promise

52

In-category differentiation

30

Evidence quality

42

Translational signal

28

Research bench value

60

Rationale SRT1720 scores as a niche probe because its primary research value is now confined to rodent SIRT1 pharmacology studies where its established mouse PK is an asset; the compound was deliberately retired as a translational candidate when Sirtris developed SRT2104 with better human pharmacokinetics, and the 2010 Pacholec et al. mechanism challenge still casts interpretive overhead on legacy studies even though the allosteric story was partially rehabilitated by Hubbard et al. in 2013.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective SIRT1 activator

An imidazothiazole SIRT1 activator; the structural lineage compound from which SRT2104 was developed.

Abstract

SRT1720 (CAS 925434-55-5; molecular formula C22H19N5OS2; molecular weight 433.55) is an imidazothiazole SIRT1 activator developed at Sirtris Pharmaceuticals as a potent (approximately 1000-fold over resveratrol) and selective sirtuin 1 activator. Mechanism is allosteric SIRT1 activation comparable to SRT2104. Mouse studies demonstrated lifespan extension in diet-induced obese mice, improved metabolic parameters, and reduced age-related pathology. The compound was the foundation for the broader Sirtris drug discovery program; SRT2104 was developed as a more drug-like successor with better human pharmacokinetics. SRT1720 is used preferentially in academic research where the established mouse pharmacology is valuable. Plasma half-life is approximately 8 to 10 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-302Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Etiracetam

Plain-language summaryIntrigue 32 / 100

Etiracetam is the racemic precursor of levetiracetam. The R-enantiomer is largely inactive; the S-enantiomer is levetiracetam. Used as a research tool to study the levetiracetam mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

16/100

The racemic parent of levetiracetam, superseded by chiral resolution and offering no research advantage over the pure active enantiomer

Look, etiracetam is essentially a solved problem in medicinal chemistry that nobody needed to return to. UCB Pharma developed it in the 1970s as a piracetam analog, investigated it briefly in early antiseizure pharmacology, then did what any competent chemist would do: resolved the racemate, identified that the S-enantiomer carries essentially all of the SV2A-mediated activity, and shelved the parent compound. That’s the whole story. The field moved on in the 1980s and hasn’t looked back.

The mechanism picture reflects this directly. SV2A-mediated pharmacology is well-characterized at this point, and levetiracetam’s binding profile has been studied extensively across multiple labs and decades. Etiracetam doesn’t add any mechanistic insight you don’t already get from levetiracetam. It just dilutes the active compound 1:1 with a biologically inert R-enantiomer at the primary target. If you want to probe SV2A, you use levetiracetam. If you want the R-enantiomer specifically, you source it separately. There’s no design where the racemate is the right tool.

On differentiation, this is about as close to “strictly worse than alternatives” as you’ll find in any research library. Levetiracetam is on formulary globally, has decades of well-characterized pharmacology, and answers the SV2A question better by construction. The differentiation score bottoms out because the compound’s own development history is the argument against it.

The evidence picture is correspondingly thin. Contemporary literature treats etiracetam almost entirely as a footnote in the levetiracetam origin story. There are no active clinical programs, no replicated modern preclinical investigations, no contemporary pharmacokinetic or pharmacodynamic studies in humans conducted on etiracetam as an object of interest in its own right. Citations to etiracetam in modern papers nearly always take the form: “levetiracetam was developed from its racemate” and nothing more.

We do score bench value modestly above zero because theres a narrow legitimate use case: comparative studies examining whether the R-enantiomer contributes anything to observed in vivo effects through off-target mechanisms, or analytical chemistry reference work. That’s real. But it’s a niche probe application for a very specific research question, not an active research target for a serious program. Honestly, the only reason this compound belongs in a library at all is completeness, not because any researcher should be prioritizing it in 2025.

Novelty

12

Mechanism promise

20

In-category differentiation

8

Evidence quality

18

Translational signal

12

Research bench value

30

Rationale Etiracetam scores low across nearly every axis because it is literally superseded by its own chiral resolution; levetiracetam is strictly better for any SV2A research, and the R-enantiomer is biologically inert at the primary target. The only residual bench value is as a chirality reference or comparative probe in narrow enantioselectivity studies, and even that use case is thin.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pyrrolidinone racetam (parent racemate of levetiracetam)

The racemic parent compound of levetiracetam, retained primarily as a research chemical and historical reference compound.

Abstract

Etiracetam (UCB 6215; α-ethyl-2-oxo-1-pyrrolidineacetamide; CAS 33996-58-6; molecular formula C8H14N2O2; molecular weight 170.21) is the racemic parent compound of levetiracetam, originally developed at UCB Pharma in the 1970s as a piracetam analog with a 2-ethyl substitution on the acetamide. The compound is a 1:1 mixture of (R)- and (S)-enantiomers; the (S)-enantiomer (levetiracetam) carries essentially all of the SV2A-mediated antiseizure activity, while the (R)-enantiomer is biologically inactive at the same target. Etiracetam was investigated in early antiseizure pharmacology in the 1980s but was superseded by the chiral resolution to levetiracetam, which became the marketed product. The compound has no current regulatory approval and is sold as a research chemical. Pharmacokinetics and dose ranges parallel levetiracetam at 2-fold the dose to account for the inactive enantiomer. There is essentially no contemporary clinical literature on etiracetam itself; references largely cite it as the parent of levetiracetam.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-035Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Picamilon

Plain-language summaryIntrigue 50 / 100

Picamilon is a Russian-developed conjugate of niacin (vitamin B3) and GABA. The niacin portion carries GABA across the blood-brain barrier. Used in Russia for circulation and anxiety. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Soviet-era niacin-GABA prodrug with clever BBB concept but thin modern evidence and limited research utility

Look, the core idea behind picamilon was actually clever for 1975. GABA doesn’t cross the blood-brain barrier on its own, so Soviet pharmacologists conjugated it to niacin, which does. Central hydrolysis was supposed to release both components and produce a combined anxiolytic-plus-vasodilatory effect. As a prodrug strategy, its fine. The problem is that we’ve known exactly how this works for decades, the components are completely mundane, and the literature supporting it is almost entirely Soviet-era Russian research that isn’t held to the methodological standards we’d want to see today.

On novelty, there’s nothing to argue about. The compound is fifty years old, approved in Russia for cerebrovascular insufficiency and anxiety, and the mechanism has been understood since its original synthesis. The niacin vasodilation story is textbook pharmacology; the GABA-ergic anxiolysis is equally unremarkable. What the conjugation adds is BBB penetrance, which is a real pharmacological contribution, but that contribution was made a long time ago and doesn’t translate into research excitement now.

The evidence situation is genuinely problematic. The clinical literature lives almost exclusively in Soviet and Russian journals from the 1970s through 1990s, with the methodological limitations that implies. There’s no meaningful Western replication. Russia’s national approval reflects a different regulatory context and era. The FDA has explicitly issued warnings against picamilon’s sale as a dietary supplement in the United States, citing that it doesn’t meet the legal definition of a dietary ingredient. That’s not a disqualifier for a research-use compound, but it does signal how regulators are reading the evidence base.

From a bench utility perspective, we struggle to identify what question picamilon lets you answer that you couldn’t answer better with other tools. For central GABA biology, phenibut and the benzodiazepine pharmacology toolbox are more characterized. For cerebrovascular work, there are better vasodilatory probes. For anxiolysis research, the GABA-A positive allosteric modulator literature is far more sophisticated. Picamilon sits at the intersection of several areas without being the best tool in any of them.

Honestly, the compound’s most interesting research angle might be as a case study in Soviet psychopharmacology and the BBB-penetrant prodrug design philosophy. That’s historically interesting but it’s not going to move a modern research program. We think the compound is fine as a historical artifact and the original prodrug concept still has teaching value, but as an object of new bench-scale investigation, there are better places to put time and resources in 2025.

Novelty

22

Mechanism promise

32

In-category differentiation

28

Evidence quality

30

Translational signal

33

Research bench value

22

Rationale Picamilon scores low primarily because both the novelty and the bench utility are exhausted: the BBB-penetrant GABA prodrug concept was genuinely clever in the 1970s but the underlying biology is now utterly mundane, and the evidence base is almost entirely Soviet-era Russian literature that doesn’t meet modern methodological standards. The Russian national approval gives it minimal translational credit, but there’s essentially no Western replication and better probes exist for every niche this compound occupies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Niacin-GABA conjugate

A Soviet-developed niacin-GABA conjugate (N-nicotinoyl-GABA) that crosses the blood-brain barrier and dissociates centrally to release both components.

Abstract

Picamilon (Pikamilon; N-nicotinoyl-GABA; CAS 34562-97-5; molecular formula C10H12N2O3; molecular weight 208.21) is a conjugate of niacin (nicotinic acid) and GABA developed in the Soviet Union in the 1970s. The niacin moiety provides blood-brain barrier permeability that GABA lacks; central hydrolysis releases both components. Niacin produces vasodilation and the GABA produces anxiolytic and mild sedative effects. The combination is approved in Russia for cerebrovascular insufficiency, anxiety, and migraine prophylaxis. Pharmacokinetics: rapid oral absorption; central hydrolysis to niacin and GABA; the niacin component is hepatically conjugated and excreted while GABA is metabolized through normal GABA pathways. Doses are 50 to 300 mg per day in divided administrations. The compound is sold as a research chemical/supplement in the United States though FDA has issued warnings against its sale as a dietary supplement.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-068Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
hGH Fragment 176-191

Plain-language summaryIntrigue 50 / 100

HGH Fragment 176-191 is the natural C-terminal fragment of human growth hormone (the parent peptide of AOD-9604). It is hypothesized to drive selective fat loss without affecting blood sugar or causing the systemic effects of full growth hormone. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

53/100

The canonical GH axis reference standard, evidence-rich but offering minimal research novelty in 2026

Look, somatropin is one of the most thoroughly characterized protein drugs ever made. Approved since 1987, studied in tens of thousands of patients across pediatric GHD, Turner syndrome, Prader-Willi, HIV wasting, short bowel syndrome, and adult GHD. The evidence base here is genuinely massive. If you need a clean, well-replicated signal that something is biologically real and clinically durable, somatropin delivers it. Thats not in dispute.

The problem, from a research library standpoint, is that the compound is almost completely understood. Receptor dimerization at GHR, JAK2 activation, STAT5 phosphorylation, hepatic IGF-1 synthesis, IGFBP-3 ternary complex assembly. This is the kind of biology you teach in first-year endocrinology. The mechanism is not novel, the axis is not under-explored, and the pharmacology is saturated. What we like about HGH is precisely the thing that makes it a poor research target: it is entirely legible. You already know what it does.

We also have to be honest about where the interesting work lives right now. Investigators pushing GH axis biology are mostly working on GHRH analogs (tesamorelin, CJC-1295), ghrelin-mimetic GHRPs (ipamorelin, hexarelin), small-molecule secretagogues like MK-677, or long-acting somatropin conjugates like somapacitan and lonapegsomatropin. The secretagogue literature is livelier than direct GH replacement, partly because preserving pulsatility matters and partly because the regulatory and sourcing landscape for secretagogues is more tractable at bench scale. Full-length recombinant GH is also expensive, cold-chain-dependent, and immunogenic in some preparations. These arent disqualifying issues, but they complicate the research workflow relative to a clean synthetic peptide.

Where somatropin still earns real points is bench utility and translational weight. If you’re doing mechanistic work on the GH/IGF-1 axis, it remains the gold standard reference. Any study that needs to compare a secretagogue’s IGF-1 response against direct GH replacement needs somatropin. The approvals also mean the pharmacokinetic and safety dataset is irreplaceable for comparative work. We don’t want to understate that. But as a primary research target, a compound this well-characterized really does belong in a support role rather than at the frontier. The field moved on. The interesting questions about GH biology now orbit around tissue selectivity, pulsatility engineering, and combinations with GLP-1 axis agents. Somatropin is the baseline you measure from, not the thing you’re running toward.

Novelty

18

Mechanism promise

32

In-category differentiation

58

Evidence quality

85

Translational signal

82

Research bench value

65

Rationale Somatropin scores very high on evidence quality and translational signal because it IS the approved drug with decades of phase 3 data, but novelty and mechanism scores drag the composite down hard; the GH/IGF-1/JAK2-STAT5 axis is textbook endocrinology, and the interesting frontier work has migrated to secretagogues, long-acting analogs, and downstream IGF-1 axis modulators rather than exogenous full-length GH replacement itself.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

C-terminal hGH fragment

The unmodified C-terminal fragment of hGH (residues 176-191) sold as a research chemical for lipolytic applications.

Abstract

hGH Fragment 176-191 is the unmodified C-terminal 16-residue sequence of human growth hormone (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe with a disulfide bond). The compound is a precursor to AOD-9604 (which adds a tyrosine N-terminal extension) and is sold as a research chemical with similar lipolytic claims. The mechanistic and clinical evidence base is essentially the same as for AOD-9604. The compound is not approved by any regulatory authority. Research-grade vendor doses are typically 250 to 500 micrograms subcutaneously daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-086Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Oxytocin

Plain-language summaryIntrigue 72 / 100

Oxytocin is the social bonding and childbirth hormone, a 9-amino-acid peptide. Used clinically to induce labor and control postpartum bleeding. Off-label and research interest in social bonding, autism spectrum disorders, and PTSD. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

Canonical OTR probe with clean obstetric evidence; intranasal CNS research has largely underdelivered

Look, oxytocin is one of those compounds where the story sounds better than the data actually reads. It’s an endogenous nonapeptide, hypothalamic origin, posterior pituitary release. The basic biology has been textbook for decades. The FDA approval for labor induction and postpartum hemorrhage is real and well-earned; that translational arrow is clean and strong. But that’s not why most research groups are pulling it off the shelf today.

The interesting research angle has been intranasal oxytocin for autism spectrum disorder, PTSD, social anxiety, and pair bonding. This has been one of the more disappointing stories in translational neuropharmacology over the last fifteen years. The Simon Baron-Cohen and Ernst Fehr groups generated genuinely exciting early data around 2010-2013 on social cognition and trust behavior. The mechanism story was compelling: OTR activation in the amygdala modulating threat appraisal, OTR in the nucleus accumbens influencing reward-based social behavior. It made sense on paper.

Then replication hit this literature hard. The Bethlehem et al. (2017) Lancet Psychiatry RCT in ASD, multi-site and well-powered, didn’t find meaningful benefit. The Guastella group’s replication work showed high effect-size heterogeneity across studies. The core problem, which still isnt resolved, is whether intranasal oxytocin actually reaches the brain in meaningful concentrations. Some investigators argue it acts peripherally on vagal afferents and OTR in circumventricular organs. Others think direct CNS entry occurs but in a dose and individual-variable manner. That debate is live and unresolved, and it cuts directly at the bench utility of the compound for the programs investigators care about most.

We think the bench value remains real for specific programs. If you’re running a social behavior study in rodents, investigating OTR distribution, or studying parturition physiology, oxytocin is what you need and thats not changing. The pharmacology around OTR subtypes, signal bias, and receptor trafficking is genuinely active and underexplored at the mechanistic level. What we dont like is the enthusiasm that still surrounds the psychiatric indications given how consistently those trials have underperformed.

The mechanism is single-receptor, known for decades, not unusual. Differentiation is structural: it’s the canonical OTR agonist and theres no real alternative probe, but that’s a position of necessity rather than pharmacological innovation. Evidence quality overall sits high because of the approved use and massive literature base, but for the research indications most investigators actually care about, the signal is frankly thin. Oxytocin belongs in your library if you’re doing OTR biology or reproductive physiology; for social cognition and psychiatric programs, honest assessment suggests the field has more questions than answers, and the translational promise hasn’t materialized.

Novelty

22

Mechanism promise

30

In-category differentiation

45

Evidence quality

60

Translational signal

35

Research bench value

55

Rationale Oxytocin is the reference compound for OTR biology with a massive, FDA-backed evidence base in reproductive medicine, but the headline research angle (intranasal delivery for autism, PTSD, social cognition) has produced mixed-to-negative results across multiple large RCTs, and CNS penetration after intranasal administration remains mechanistically contested, deflating novelty, mechanism, and translational scores significantly.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous nonapeptide neuropeptide/hormone

An endogenous nonapeptide produced in the hypothalamus and released by the posterior pituitary, with maternal, social bonding, and anxiolytic effects.

Abstract

Oxytocin (CAS 50-56-6; molecular formula C43H66N12O12S2; molecular weight 1007.19) is an endogenous nonapeptide hormone synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released systemically by the posterior pituitary. The compound is FDA-approved for labor induction and postpartum hemorrhage (intravenous). Beyond reproductive applications, intranasal oxytocin has been studied extensively for autism spectrum disorder, social anxiety, PTSD, and pair bonding research, with mixed clinical results. Mechanism is oxytocin receptor (OTR) agonism. Pharmacokinetics: plasma half-life ~3 to 6 minutes; central CNS penetration after intranasal administration is debated. Doses for research applications are typically 24 IU intranasally per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-135Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lemborexant

Plain-language summaryIntrigue 72 / 100

Lemborexant, sold as Dayvigo, is a second-generation dual orexin receptor antagonist with improved selectivity for OX2 over OX1. FDA-approved for insomnia in 2019. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

Second DORA with refined PK but no novel mechanism; useful clinically, limited bench excitement

Look, the DORA class is genuinely interesting biology. Blocking orexin signaling to let sleep initiate naturally is a fundamentally more elegant approach than hammering GABA-A with benzos or Z-drugs, and the orexin system touches enough downstream biology (metabolism, reward, arousal, thermoregulation) that serious investigators are still mapping its reach. We like that framing. The problem is that suvorexant already got there in 2014, established the mechanism, and built the early research scaffolding. Lemborexant is the second car in the lot.

The clinical differentiation is real but modest. Lemborexant has a somewhat faster-declining active fraction than suvorexant, which translated into statistically improved next-day psychomotor performance in the SUNRISE-1 and SUNRISE-2 trials. Eisai ran solid Phase 3 RCTs; the FDA approved it in 2019. Evidence quality is genuinely good for an insomnia drug, and the clinical signal is clear: it works, it’s well-tolerated, next-day grogginess is less of a problem than with older agents. That earns points. But those points are clinical pharmacology points, not research frontier points.

Here’s the thing: from a bench perspective, what does lemborexant let you do that suvorexant doesn’t? Both are competitive dual OX1R/OX2R antagonists. If you’re using a DORA as a probe to dissect orexin circuit biology, suvorexant has a larger research literature behind it and more years of investigator familiarity. Daridorexant (Quviviq) arrived in 2022 with additional comparative data. Lemborexant sits in the middle of a growing class without claiming either first-mover status or uniquely differentiated pharmacology. For any serious research program building around orexin biology, theres more leverage in selective OX1R or OX2R ligands (SB-334867, EMPA, JNJ-61393178) than in a second-in-class approved DORA.

We don’t want to dismiss the compound entirely. The orexin system research space is active and still has real open questions: the OX1R-versus-OX2R contribution to different sleep architecture features, cross-talk with the HPA axis, the metabolic regulation angle. A well-characterized approved DORA does have utility as a reference compound in that work. But lemborexant specifically adds little that suvorexant doesn’t already provide as a probe, and that limits its research bench value meaningfully.

Honestly, this is a compound that belongs in a clinical pharmacist’s formulary more than on a research scientist’s priority list. The score reflects a real, approved, well-evidenced drug with solid mechanism credentials in a class that matters, discounted heavily for being second-in-class with no novel angle worth chasing in 2024 bench science.

Novelty

35

Mechanism promise

52

In-category differentiation

28

Evidence quality

72

Translational signal

58

Research bench value

28

Rationale Lemborexant earns real marks for solid Phase 3 RCT evidence and a mechanistically elegant class (DORA), but it’s the second approved compound in a mechanism suvorexant already pioneered, and its differentiation story is almost entirely pharmacokinetic rather than pharmacodynamic. The schedule IV cap (75 max) doesn’t bind since the rubric naturally lands well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual orexin receptor antagonist

A second DORA FDA-approved as Dayvigo (2019) for insomnia, with shorter half-life and reduced next-day residual effects than suvorexant.

Abstract

Lemborexant (Dayvigo; E2006; CAS 1369764-02-2) is a dual orexin receptor antagonist developed by Eisai and approved by the FDA in 2019 for insomnia. The compound has shorter plasma half-life (17 to 19 hours, but the active fraction declines more rapidly than with suvorexant) and reduced next-day residual sedation in clinical trials. Mechanism is the same as suvorexant: competitive OX1R and OX2R antagonism. Approved doses are 5 to 10 mg at bedtime. Schedule IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-151Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dynamine (Methylliberine)

Plain-language summaryIntrigue 38 / 100

Dynamine (methylliberine) is a purine alkaloid related to theacrine, marketed in pre-workout formulations as a longer-lasting alternative to caffeine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

22/100

Proprietary purine alkaloid with derivative caffeine-like mechanism and manufacturer-funded evidence base

Look, Dynamine is a supplement industry compound first and a research target second. Methylliberine is a purine alkaloid isolated from kucha tea, a close structural relative of theacrine and, further up the family tree, caffeine. The proposed mechanism is adenosine receptor antagonism, which puts it squarely in one of the most thoroughly worked territories in pharmacology. When your mechanism is “probably like caffeine but maybe a bit faster,” you’re not giving a bench scientist much to get excited about.

The compound’s commercial origin shapes everything about the evidence base. Compound Solutions holds the trademark on Dynamine, and most of the available research is either funded by or conducted in direct collaboration with the licensor. There are a handful of small, acute studies examining subjective energy and focus outcomes in healthy adults; the designs are typically crossover, N is small, and independent replication is essentially absent. The “faster onset than theacrine” claim reads like a product differentiation pitch rather than a mechanistic finding that tells you anything actionable about the underlying pharmacology.

Here’s what we actually dont know: the full receptor binding profile. The adenosine antagonist claim is plausible given structural similarity to caffeine and theacrine, but specific affinity data for A1 and A2A subtypes is not clearly available in the open literature. That ambiguity might sound like a research opportunity. It isn’t. It’s more likely a sign that no serious academic group has prioritized the question in the seven-plus years since the ingredient was introduced to market. When industry-funded compounds fail to generate independent academic traction in that window, the absence is informative.

For probe value, caffeine remains the gold-standard adenosine antagonist for bench work, with decades of receptor binding data, knockout models, and well-characterized dose-response relationships behind it. If you’re doing A2A biology, you have better tools. If you’re interested in comparative pharmacokinetics within the purine alkaloid class, theacrine’s tolerance profile has at least generated some independent investigation; methylliberine’s PK data is thin. There’s no assay, no pathway, no model system where Dynamine opens a door that better-characterized compounds don’t already open more cleanly.

We don’t think this earns shelf space in a serious research library. It’s a trademarked supplement ingredient backed by a handful of company-sponsored trials and a plausible but uncharacterized mechanism. If the purine alkaloid space genuinely interests you, the research resources are better spent on theacrine’s habituation biology or the broader adenosine receptor field, where actual frontier work is happening.

Novelty

32

Mechanism promise

18

In-category differentiation

20

Evidence quality

18

Translational signal

22

Research bench value

18

Rationale Methylliberine’s proposed mechanism is adenosine antagonism, pharmacologically indistinguishable in kind from caffeine and theacrine, and the evidence base is almost entirely licensor-funded with no meaningful independent replication. The compound earns modest novelty points for being a relatively recent structural variant, but nothing in the available literature justifies prioritizing it over better-characterized tools in the same class.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Purine alkaloid (methylliberine)

A purine alkaloid related to theacrine, present in kucha tea, marketed as Dynamine for energy and focus applications.

Abstract

Dynamine (methylliberine; 9-methylliberine) is a purine alkaloid related to theacrine and present in kucha tea (Camellia kucha). The compound is marketed as Dynamine by Compound Solutions for energy and focus applications. Pharmacology likely overlaps with the broader methylxanthine class (adenosine antagonism) but specific receptor profile and clinical evidence base are limited. Doses are typically 50 to 200 mg per administration; Compound Solutions describes it as having faster onset than theacrine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-166Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Taurine

Plain-language summaryIntrigue 60 / 100

Taurine is a sulfonate amino acid abundant in heart, retina, and brain. Conditional rather than essential (the body makes it from cysteine). Has cardioprotective, anti-inflammatory, and GABAergic effects. Found in energy drinks where the contribution to performance is contested. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

32/100

Basic endogenous sulfonate with an interesting 2023 longevity paper but fundamentally mature and low bench priority

Cap applied basic amino acid cap (32)

Yeah, taurine. The Singh et al. 2023 Science paper put this on a lot of radars, and we get why. A multi-species lifespan and healthspan study in a top journal, showing that plasma taurine declines with age and that supplementation partially reverses that decline in mice, worms, and cynomolgus monkeys, thats genuinely interesting. We’re not dismissing it.

But here’s the thing: taurine is still an endogenous sulfonate that’s been in the literature since the 1970s. It’s in energy drinks. Your cat food is fortified with it. The mechanisms, including bile acid conjugation, osmotic regulation, calcium handling in cardiac tissue, and modulation of GABA and glycine receptor activity, are textbook biology at this point. None of that is novel territory, and none of it gives an investigator a new handle on a hard problem.

What the Singh paper actually does is give an old compound a new frame: if circulating taurine is a biomarker of biological aging, and supplementation restores youthful levels, then you have a plausible longevity rationale that wasn’t clearly articulated before. The effect sizes in mice were meaningful, around 10 to 12 percent lifespan extension, and the monkey healthspan marker data is intriguing. But the human arm of that study was observational, not interventional. There is no RCT demonstrating human longevity benefit, and the bench-to-clinic gap for longevity endpoints is one of the hardest translation problems in the field.

The cardiovascular and exercise literature is older and reasonably solid. Taurine has real roles in cardiac calcium handling; there’s clinical evidence for benefits in heart failure patients at gram-level doses. The exercise literature is mixed. None of it is particularly surprising given the known mechanisms.

As a research tool, taurine has limited probe value. If you’re studying GABAergic or glycinergic neurotransmission, there are more selective tools. If you’re studying longevity pathways, MOTS-c, rapamycin, or even GLP-1 class compounds offer more mechanistic traction. Taurine’s bench utility is mostly in confirming effects you already suspect rather than uncovering new biology.

Honestly, if you’re building a research program around the Singh findings, the interesting question isn’t whether taurine supplementation does something, but why taurine declines with age and what upstream process drives that. Taurine itself is probably not the most productive research object. The 2023 paper is a pointer, not a destination, and at Kodiac we’d deprioritize this one relative to compounds with genuinely novel mechanisms or more compelling human interventional evidence.

Novelty

26

Mechanism promise

30

In-category differentiation

20

Evidence quality

55

Translational signal

40

Research bench value

35

Rationale Singh et al. 2023 (Science) gives taurine a genuine new angle with multi-species lifespan data and the plasma-decline-with-age framing, pushing evidence and translational scores above floor; however, the compound is still an endogenous sulfonate with textbook-level mechanisms and no human interventional longevity RCT, so the raw overall clears the basic-aa cap and the cap binds at 32.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Conditional amino acid / sulfonate

An endogenous sulfonate amino acid with osmolyte, calcium-handling, and bile acid conjugation roles, recently associated with longevity in animal models.

Abstract

Taurine (2-aminoethanesulfonic acid; CAS 107-35-7; molecular formula C2H7NO3S; molecular weight 125.15) is an endogenous sulfonate “amino acid” (taurine has a sulfonate group rather than a carboxylate) with widespread tissue distribution and multiple physiological roles: bile acid conjugation, osmotic regulation, calcium handling in cardiac tissue, and modulation of GABA and glycine neurotransmission. Plasma taurine declines with age. A 2023 Science paper (Singh et al.) demonstrated that taurine supplementation extends lifespan and healthspan in mice, monkeys, and worms; the result generated significant interest in taurine as a longevity intervention. Doses for longevity applications are typically 3 to 6 grams per day; doses for cardiovascular and exercise applications are 1 to 6 grams. Excellent safety profile.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-182Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
1,2,3,4-Tetrahydroisoquinoline (THIQ)

Plain-language summaryIntrigue 45 / 100

1,2,3,4-Tetrahydroisoquinoline (THIQ) is an endogenous and exogenous alkaloid with research interest in dopaminergic systems and neurodegenerative disease. The compound and its derivatives are studied as Parkinson disease research tools. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous and exogenous alkaloid

A simple isoquinoline scaffold present endogenously and as a structural element of many alkaloid pharmacophores; also studied for MAO modulation.

Abstract

1,2,3,4-Tetrahydroisoquinoline (THIQ; CAS 91-21-4; molecular formula C9H11N; molecular weight 133.19) is a simple isoquinoline alkaloid scaffold present endogenously in mammalian brain (formed by Pictet-Spengler condensation of phenethylamine and formaldehyde or related aldehydes) and as a structural component of many pharmacological alkaloids. Endogenous THIQs are implicated in some neurodegenerative processes (the 1-methyl-THIQ derivative is structurally similar to MPTP, the Parkinsonism-inducing toxin). The unsubstituted THIQ has been studied as a research probe for monoamine oxidase modulation and dopaminergic system effects. Not in clinical use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-199Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 40 41 42 43 44 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.